

Herceptin	Trastuzumab	Anti-HER2; humanized IgG1κ	2000 (1998)	Genentech	Metastatic breast cancer with tumor overexpression of HER2 protein	IV infusion
Humaspect	Votumumab	Anti-cytokeratin tumor associated antigen; human mAb	1998, withdrawn in 2003	Organon Teknika	Detection of carcinoma of the colon or rectum	IV infusion
Humira	Adalimumab	Anti TNF; human IgG1κ	2003 (2002)	CAT and Abbott	RA patients not responding to DMARDs. Blocks TNF-alpha	SC
Ilaris	Canakinumab	Anti-IL1β; human IgG1	2009 (2009)	Novartis	Muckle-Wells syndrome	SC
Indimacis 125	Igovomab	Anti-tumor associated antigen CA 125; murine Fab ₂	1996, withdrawn in 2009	CIS Bio	Diagnosis of cutaneous melanoma lesions	IV infusion
Kadcyla	Trastuzumab emtansine	Anti-Her2; humanized IgG1; immunoconjugate	In review (2013)	Genentech/Roche	Breast cancer	IV infusion
Keytruda	Pembrolizumab	Anti-PD1b, humanized mAb	2014	Merck	Advanced melanoma	IV
Lucentis	Ranibizumab	Anti-VEGF; humanized IgG1κ Fab fragment	2007 (2006)	Genentech	Age-related wet macular degeneration	Intravitreal injection
LeukoScan	Sulesomab	Anti-NCA 90, a surface granulocyte nonspecific cross-reacting antigen; murine mAb labeled with 99m technetium	1997	Immunomedics	Diagnostic imaging for infection and inflammation in bone of patients with osteomyelitis	IV
Mylotarg	Gemtuzumab ozogamicin	Anti-CD33; humanized IgG4κ conjugated to calicheamicin	NA (2000)	Celltech and Wyeth	Treatment of CD33 positive acute myeloid leukemia	IV infusion

Continued